A Forward Look, The Year Ahead - Featured Research on ViroPharma Incorporated and Salix Pharmaceuticals, Ltd.
(firmenpresse) - HONG KONG -- (Marketwire) -- 02/15/12 -- Today, introduced featured coverage of ViroPharma Incorporated (NASDAQ: VPHM) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Full research reports are available to readers at: .
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected ViroPharma Incorporated for its current position within the healthcare industry. ViroPharma Incorporated (ViroPharma) is a global biotechnology company focused on the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. A copy of this report featuring ViroPharma Incorporated (NASDAQ: VPHM) is available at: .
Bollinger Report is featuring Salix Pharmaceuticals, Ltd. for its changing role within the healthcare industry. Salix Pharmaceuticals, Ltd. is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. To download researches and analysis on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) we welcome investors to visit: .
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.
Contact:
Martin Schwartz
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.02.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 1083312
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HONG KONG
Phone:
Kategorie:
Investment Services & Trading
Anmerkungen:
Diese Pressemitteilung wurde bisher 55 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"A Forward Look, The Year Ahead - Featured Research on ViroPharma Incorporated and Salix Pharmaceuticals, Ltd.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bollinger Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
